Report Overview:

[135 Pages Report] Lung cancer surgery is an operation performed for treating lung cancer, particularly non-small cell lung cancer. This study of the lung cancer surgery market primarily pertains to the lung cancer surgical devices market. Surgical procedures are covered separately in this report, as part of the lung cancer surgical procedures market.

The lung cancer surgery market is projected to reach USD 29.99 billion by 2021 from USD 21.58 billion in 2016, at a CAGR of 6.8% from 2016 to 2021. The major factors driving the growth of this market are increasing incidence and prevalence of lung cancer, rapid growth in the aging population, and growing healthcare expenditure worldwide. On the other hand, high cost of lung cancer surgeries is the major factor that is expected to restrain the growth of this market during the forecast period.

Technological Advancements in Lung Cancer Treatment

Currently, robot-assisted surgery, minimally invasive surgeries (such as video-assisted thoracoscopic surgeries), and percutaneous trans-catheter surgeries (such as radiofrequency ablation and cryo ablation) are some of the advanced surgical procedures that are used in the treatment of lung cancer. As compared to conventional open surgeries, these advanced procedures offer various advantages such as shorter hospital stay, shorter chest tube duration, less blood loss, and smaller incisions. As a result, the preference for these procedures is higher among patients as well as surgeons. Considering the implications of these technological advancements on patient safety, patient comfort, and surgical outcomes, the demand for technologically advanced approaches for the treatment of lung cancer is expected to increase in the coming years.

Opportunity: Untapped Emerging Markets

Emerging markets, such as China, India, and Brazil, offer significant growth opportunities for players operating in the lung cancer surgery market. These countries are expected to witness high growth in the coming years, owing to the presence of less stringent regulatory policies and low competition. Moreover, the growing prevalence of lung cancer is expected to increase the number of lung cancer surgeries in these emerging markets. According to GLOBOCAN, in 2015, the total incidence of lung cancer in emerging markets such as China, India, and Brazil was around 0.84 million and this figure is expected to reach 0.9 million by 2020. As a result of increasing disposable incomes, the healthcare expenditure in these economies is increasing rapidly. Between 2003 and 2012, growth rates for healthcare expenditure in Asia and the RoW were 11.2% and 13.9%, respectively. According to estimates from the World Bank, healthcare spending in India increased from 4.3% of GDP in 2005 to 4.7% of GDP in 2015. Additionally, growing purchasing power has enabled the patient population in emerging countries to opt for technologically advanced medical services and solutions. This in turn is expected to drive the demand for advanced medical devices, including minimally invasive surgery products, in these countries.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222

Lung Cancer Market, by Surgical Devices

 Surgical Instruments
Hand Instruments
Stapler
Forceps
Retractors
Rib Shear
Trocars
Cutters
Clamps
Scissors
Elevators
Other Hand Instruments
Monitoring and Visualizing Systems
Cameras and Video Support
Endoscopic Trocars with Optical View
Endosurgical Equipment

Lung Cancer Market, by Surgical Procedures

Thoracotomy
Lobectomy
Sleeve Resection
Segmentectomy
Pneumonectomy
Minimally Invasive Surgeries

Lung Cancer Surgery Market, by Region

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia
China
Japan
India
Rest of Asia
Rest of the World

Key Market Players:

Ethicon US LLC (U.S.), Intutive Surgical Inc. (U.S.), Olympus Corporation (Japan), Accuray Inc. (U.S.) and Teleflex Inc. (U.S.).

Inquiry about lung cancer surgery market before buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=222